CY1119434T1 - Νεες διυδροπυριμιδινοϊσοκινολινονες και φαρμακευτικες συνθεσεις αυτων για τη θεραπεια φλεγμονωδων διαταραχων - Google Patents
Νεες διυδροπυριμιδινοϊσοκινολινονες και φαρμακευτικες συνθεσεις αυτων για τη θεραπεια φλεγμονωδων διαταραχωνInfo
- Publication number
- CY1119434T1 CY1119434T1 CY20171101053T CY171101053T CY1119434T1 CY 1119434 T1 CY1119434 T1 CY 1119434T1 CY 20171101053 T CY20171101053 T CY 20171101053T CY 171101053 T CY171101053 T CY 171101053T CY 1119434 T1 CY1119434 T1 CY 1119434T1
- Authority
- CY
- Cyprus
- Prior art keywords
- diseases
- treatment
- pharmaceutical compositions
- dihydropyrimidinoinkinolinones
- new
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004968 inflammatory condition Effects 0.000 abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 1
- 102100033864 G-protein coupled receptor 84 Human genes 0.000 abstract 1
- 101001069589 Homo sapiens G-protein coupled receptor 84 Proteins 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 208000030172 endocrine system disease Diseases 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002314 neuroinflammatory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578979P | 2011-12-22 | 2011-12-22 | |
| PCT/EP2012/076275 WO2013092791A1 (en) | 2011-12-22 | 2012-12-20 | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119434T1 true CY1119434T1 (el) | 2018-03-07 |
Family
ID=47520068
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101053T CY1119434T1 (el) | 2011-12-22 | 2017-10-11 | Νεες διυδροπυριμιδινοϊσοκινολινονες και φαρμακευτικες συνθεσεις αυτων για τη θεραπεια φλεγμονωδων διαταραχων |
| CY20221100292T CY1125167T1 (el) | 2011-12-22 | 2022-04-18 | Διυδροπυριμιδινοϊσοκινολινονες και φαρμακευτικες συνθεσεις αυτων για τη θεραπεια σκληρυνσης κατα πλακας |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100292T CY1125167T1 (el) | 2011-12-22 | 2022-04-18 | Διυδροπυριμιδινοϊσοκινολινονες και φαρμακευτικες συνθεσεις αυτων για τη θεραπεια σκληρυνσης κατα πλακας |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US8927543B2 (https=) |
| EP (3) | EP3378862B1 (https=) |
| JP (1) | JP6062453B2 (https=) |
| KR (1) | KR102012268B1 (https=) |
| CN (1) | CN103998448B (https=) |
| AR (1) | AR089284A1 (https=) |
| AU (1) | AU2012357067B2 (https=) |
| BR (1) | BR112014015142B1 (https=) |
| CA (1) | CA2859578C (https=) |
| CL (1) | CL2014001664A1 (https=) |
| CO (1) | CO7010835A2 (https=) |
| CR (1) | CR20140305A (https=) |
| CY (2) | CY1119434T1 (https=) |
| DK (2) | DK2794604T3 (https=) |
| EA (1) | EA023826B1 (https=) |
| ES (2) | ES2643379T3 (https=) |
| HR (2) | HRP20171404T1 (https=) |
| HU (1) | HUE12812237T4 (https=) |
| IL (2) | IL233212B (https=) |
| IN (1) | IN2014MN01033A (https=) |
| LT (2) | LT2794604T (https=) |
| MX (1) | MX351681B (https=) |
| NI (1) | NI201400060A (https=) |
| PE (1) | PE20141685A1 (https=) |
| PH (1) | PH12014501178A1 (https=) |
| PL (2) | PL2794604T3 (https=) |
| PT (2) | PT3378862T (https=) |
| SG (1) | SG11201403169PA (https=) |
| SI (2) | SI3378862T1 (https=) |
| TW (1) | TWI567073B (https=) |
| UA (1) | UA111767C2 (https=) |
| UY (1) | UY34545A (https=) |
| WO (1) | WO2013092791A1 (https=) |
| ZA (1) | ZA201404607B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117095C2 (uk) | 2011-12-22 | 2018-06-25 | Аліос Біофарма, Інк. | Нуклеозидна сполука або її фармацевтично прийнятна сіль |
| AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP2935262B1 (en) | 2012-12-20 | 2017-03-15 | Galapagos NV | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
| GB201319677D0 (en) * | 2013-11-07 | 2013-12-25 | Eth Z Rich | Cyclopropanation |
| GB201411241D0 (en) * | 2014-06-25 | 2014-08-06 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201506894D0 (en) * | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| CN108530480B (zh) * | 2017-03-06 | 2022-06-28 | 中国科学院上海药物研究所 | Gpr84受体拮抗剂及其应用 |
| EP3403649A1 (en) | 2017-05-16 | 2018-11-21 | Bayer Pharma Aktiengesellschaft | Inhibitors and antagonists of gpr84 for the treatment of endometriosis |
| CN111343986A (zh) | 2017-11-15 | 2020-06-26 | 加拉帕戈斯股份有限公司 | 用于治疗纤维化疾病的化合物及其药物组合物 |
| CR20220291A (es) | 2019-12-19 | 2022-08-10 | Bayer Ag | Derivados de furoindazol |
| WO2021123394A1 (en) | 2019-12-20 | 2021-06-24 | University Of Copenhagen | G protein-coupled receptor modulators and a pharmaceutical composition |
| WO2022112186A1 (en) | 2020-11-24 | 2022-06-02 | Galapagos Nv | Compound for use in and methods of treatment of fibrotic diseases |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Ｇｐｒ８４アンタゴニストおよびその使用 |
| CA3211437A1 (en) | 2021-02-23 | 2022-09-01 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
| WO2022194267A1 (zh) * | 2021-03-18 | 2022-09-22 | 武汉人福创新药物研发中心有限公司 | 一种gpr84拮抗剂及其制备方法和用途 |
| WO2022218372A1 (zh) * | 2021-04-14 | 2022-10-20 | 武汉人福创新药物研发中心有限公司 | 一种二氢嘧啶并异喹啉酮类衍生物及用途 |
| CA3218018A1 (en) | 2021-04-29 | 2022-11-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
| US20250066335A1 (en) | 2021-06-18 | 2025-02-27 | University Of Copenhagen | Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists |
| JP7705966B2 (ja) * | 2021-06-21 | 2025-07-10 | 武漢人福創新薬物研発中心有限公司 | Ｇｐｒ８４アンタゴニストとしての三環式化合物 |
| CN115611944A (zh) | 2021-07-15 | 2023-01-17 | 中国科学院上海药物研究所 | 不对称gpr84拮抗剂及其用途 |
| WO2023076668A1 (en) * | 2021-10-29 | 2023-05-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for treatment of cancer |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| WO2024083705A1 (en) | 2022-10-18 | 2024-04-25 | Bayer Aktiengesellschaft | Furoindazole derivatives for the treatment of pain |
| CN120569392A (zh) * | 2022-12-30 | 2025-08-29 | 广州市联瑞制药有限公司 | 三环类化合物及其制备方法和应用 |
| WO2024220480A2 (en) * | 2023-04-17 | 2024-10-24 | The Board Of Trustees Of The Leland Stanford Junior University | Method for detecting innate immune action in vivo using gpr84-pet |
| CN121620356A (zh) | 2023-06-26 | 2026-03-06 | 维罗纳制药公司 | 包含恩塞芬汀的颗粒组合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2720085A1 (de) | 1977-05-05 | 1978-11-16 | Hoechst Ag | Pyrimido(6,1-a)isochinolin-2-on- derivate |
| AU744986B2 (en) * | 1997-07-12 | 2002-03-07 | Cancer Research Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
| JP2002543046A (ja) * | 1999-03-31 | 2002-12-17 | バーナリス・リミテッド | ピリミド［６，１−ａ］イソキノリン−４−オン誘導体 |
| US7501512B2 (en) * | 2003-07-08 | 2009-03-10 | Smithkline Beecham Corporation | Chemical compounds |
| WO2005050225A2 (en) | 2003-10-31 | 2005-06-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) |
| CA2621144A1 (en) | 2005-09-02 | 2007-03-08 | Arena Pharmaceuticals, Inc. | Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| US8217177B2 (en) * | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| AR073354A1 (es) | 2008-07-31 | 2010-11-03 | Genentech Inc | Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer. |
| JP2011088847A (ja) * | 2009-10-21 | 2011-05-06 | Takeda Chem Ind Ltd | 三環性化合物およびその用途 |
| BR112014015298B1 (pt) | 2011-12-22 | 2021-06-15 | Connexios Life Sciences Pvt. Ltd | Composto derivado de aza-adamantano, composição farmacêutica e uso do composto |
| AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| RU2669695C2 (ru) | 2011-12-22 | 2018-10-15 | Конекшис Лайф Сайенсиз Пвт. Лтд. | Циклические амидные производные как ингибиторы 11-бета-гидроксистероид-дегидрогеназы и их применение |
| JP5903499B2 (ja) | 2011-12-22 | 2016-04-13 | ノバルティス アーゲー | ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体 |
| EP2935262B1 (en) | 2012-12-20 | 2017-03-15 | Galapagos NV | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
-
2012
- 2012-12-17 AR ARP120104774A patent/AR089284A1/es active IP Right Grant
- 2012-12-20 TW TW101148765A patent/TWI567073B/zh not_active IP Right Cessation
- 2012-12-20 HU HUE12812237A patent/HUE12812237T4/hu unknown
- 2012-12-20 PT PT171848344T patent/PT3378862T/pt unknown
- 2012-12-20 ES ES12812237.1T patent/ES2643379T3/es active Active
- 2012-12-20 WO PCT/EP2012/076275 patent/WO2013092791A1/en not_active Ceased
- 2012-12-20 PE PE2014000988A patent/PE20141685A1/es active IP Right Grant
- 2012-12-20 PL PL12812237T patent/PL2794604T3/pl unknown
- 2012-12-20 US US13/721,788 patent/US8927543B2/en active Active
- 2012-12-20 IN IN1033MUN2014 patent/IN2014MN01033A/en unknown
- 2012-12-20 AU AU2012357067A patent/AU2012357067B2/en not_active Ceased
- 2012-12-20 ES ES17184834T patent/ES2911449T3/es active Active
- 2012-12-20 BR BR112014015142-3A patent/BR112014015142B1/pt not_active IP Right Cessation
- 2012-12-20 HR HRP20171404TT patent/HRP20171404T1/hr unknown
- 2012-12-20 SI SI201231991T patent/SI3378862T1/sl unknown
- 2012-12-20 MX MX2014007363A patent/MX351681B/es active IP Right Grant
- 2012-12-20 LT LTEP12812237.1T patent/LT2794604T/lt unknown
- 2012-12-20 DK DK12812237.1T patent/DK2794604T3/da active
- 2012-12-20 EP EP17184834.4A patent/EP3378862B1/en active Active
- 2012-12-20 DK DK17184834.4T patent/DK3378862T3/da active
- 2012-12-20 JP JP2014547997A patent/JP6062453B2/ja not_active Expired - Fee Related
- 2012-12-20 EP EP12812237.1A patent/EP2794604B1/en active Active
- 2012-12-20 CN CN201280061536.3A patent/CN103998448B/zh not_active Expired - Fee Related
- 2012-12-20 EA EA201491245A patent/EA023826B1/ru not_active IP Right Cessation
- 2012-12-20 CA CA2859578A patent/CA2859578C/en active Active
- 2012-12-20 PL PL17184834T patent/PL3378862T3/pl unknown
- 2012-12-20 SI SI201231087T patent/SI2794604T1/sl unknown
- 2012-12-20 KR KR1020147020306A patent/KR102012268B1/ko not_active Expired - Fee Related
- 2012-12-20 EP EP22155038.7A patent/EP4019519A1/en not_active Withdrawn
- 2012-12-20 UA UAA201408294A patent/UA111767C2/uk unknown
- 2012-12-20 LT LTEP17184834.4T patent/LT3378862T/lt unknown
- 2012-12-20 SG SG11201403169PA patent/SG11201403169PA/en unknown
- 2012-12-20 HR HRP20220456TT patent/HRP20220456T1/hr unknown
- 2012-12-20 PT PT128122371T patent/PT2794604T/pt unknown
- 2012-12-21 UY UY0001034545A patent/UY34545A/es unknown
-
2014
- 2014-01-06 US US14/148,057 patent/US9255095B2/en active Active
- 2014-05-26 PH PH12014501178A patent/PH12014501178A1/en unknown
- 2014-06-18 IL IL233212A patent/IL233212B/en active IP Right Grant
- 2014-06-19 NI NI201400060A patent/NI201400060A/es unknown
- 2014-06-20 CL CL2014001664A patent/CL2014001664A1/es unknown
- 2014-06-23 ZA ZA2014/04607A patent/ZA201404607B/en unknown
- 2014-06-24 CR CR20140305A patent/CR20140305A/es unknown
- 2014-07-22 CO CO14158655A patent/CO7010835A2/es unknown
-
2015
- 2015-12-11 US US14/966,879 patent/US10047083B2/en active Active
-
2017
- 2017-10-11 CY CY20171101053T patent/CY1119434T1/el unknown
-
2018
- 2018-02-18 IL IL257581A patent/IL257581A/en unknown
- 2018-05-04 US US15/971,245 patent/US11220499B2/en active Active
-
2021
- 2021-11-12 US US17/454,712 patent/US20220227751A1/en not_active Abandoned
-
2022
- 2022-04-18 CY CY20221100292T patent/CY1125167T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119434T1 (el) | Νεες διυδροπυριμιδινοϊσοκινολινονες και φαρμακευτικες συνθεσεις αυτων για τη θεραπεια φλεγμονωδων διαταραχων | |
| CY1119731T1 (el) | Διαδικασια για την παρασκευη παραγωγων χολικου οξεος | |
| CY1119422T1 (el) | Παραγωγα μπετουλινης | |
| EA201390969A1 (ru) | Модуляторы глюкагонового рецептора | |
| NZ708501A (en) | Treatment of pulmonary disease | |
| CY1118682T1 (el) | Ενωσεις πυραζολης ως αναστολεις του υποδοχεα σιγμα | |
| EA201492281A1 (ru) | Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
| EA201492285A1 (ru) | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) | |
| PH12017501911A1 (en) | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| CY1118574T1 (el) | Ενωσεις υποκατεστημενου πυριδινο-2-καρβοξαμιδιου ως αναστολεις κινασης ρυθμισης σηματος αποπτωσης | |
| CY1119231T1 (el) | Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3 | |
| MX368263B (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. | |
| CY1116791T1 (el) | 4-αρυλ-ν-φαινυλ-1,3,5-τριαζιν-αμινες που περιεχουν μια ομαδα σουλφοξιμινης | |
| PH12019502853A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| EA201391615A1 (ru) | Дейтерированные потенциаторы cftr | |
| EA201101026A1 (ru) | Ингибиторы бета-секретазы | |
| EA201690246A1 (ru) | Ингибиторы аутотаксинов, содержащие ядро гетероароматическое кольцо-бензил-амидный цикл | |
| EA201300034A1 (ru) | Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения | |
| PE20150182A1 (es) | Compuestos de fenoxietil piperidina | |
| EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
| CU24103B1 (es) | Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos | |
| AR087168A1 (es) | Compuesto derivado de pirimidina sulfonamida | |
| EA201391173A1 (ru) | Изоксазолидиновые производные | |
| MX2013006768A (es) | Moduladores de receptor de glucagon. | |
| MX2015001657A (es) | Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar). |